ADMA Biologics (ADMA) vs Mesoblast (MESO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Mesoblast (MESO) has outperformed ADMA Biologics (ADMA) over the past year, losing 22.9% versus a loss of 27.5%. Over five years, ADMA leads with a +821.8% price change compared with +22.7% for MESO. ADMA Biologics is the larger company by market cap ($2.27 billion vs $1.81 billion), about 1.3 times the size.
On valuation, ADMA Biologics trades at a lower forward P/E (10.7x vs 30.6x for Mesoblast).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | MESO |
|---|---|---|
| Share price | $10.14 | $13.94 |
| Market cap | $2.27B | $1.81B |
| 1-day change | -0.39% | +2.42% |
| YTD return | -44.41% | -22.73% |
| 1-year return | -27.52% | -22.94% |
| 5-year return | +821.82% | +22.71% |
| P/E ratio (TTM) | 14.49 | — |
| Forward P/E | 10.75 | 30.64 |
| EPS (TTM) | $0.70 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.46 | $21.50 |
| 52-week low | $7.21 | $13.05 |
| Distance from 52-week high | -50.44% | -35.16% |
| Analyst consensus | none | buy |
| Avg. price target upside | +67.65% | +165.42% |
| Average volume | 2.62M | 236.60K |
| Shares outstanding | 223.98M | 129.85M |
| Employees | 640 | 108 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees
ADMA vs MESO FAQ
Which is bigger, ADMA Biologics or Mesoblast?
ADMA Biologics (ADMA) is larger, with a market capitalization of $2.27B compared with $1.81B for Mesoblast (MESO).
Which stock has performed better over the past year, ADMA or MESO?
MESO returned -22.94% over the past 12 months, compared with -27.52% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Mesoblast in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.